Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma

Clin Lymphoma Myeloma Leuk. 2023 Sep 15:S2152-2650(23)01551-3. doi: 10.1016/j.clml.2023.09.004. Online ahead of print.ABSTRACTBlack and Latino/Hispanic populations are disproportionately impacted by multiple myeloma (MM) in the United States and are underrepresented in many clinical trials. The Multiple Myeloma Research Foundation sponsored a 1-day workshop of 46 experts spanning the ecosystem of MM research and care, including government, academia, nonprofits, pharma/biotech, community partners, and retail pharmacy. Specific, tangible steps to overcome the well-documented barriers to improving the diversity and inclusivity of clinical trials were discussed, including broadening inclusion/exclusion criteria, reducing the financial and other burdens of trial participants, selecting diverse study sites, including implicit bias training, and taking steps to empower patients.PMID:37783639 | DOI:10.1016/j.clml.2023.09.004
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research